This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Biotech Sector Weekly Rewind

BOSTON (TheStreet) -- Adam Feuerstein's take on the biotech week that was Nov. 1, 2010:

The week's best-performing stocks in the sector: Avanir Pharmaceuticals (SYMBOL) (+98%), Aastrom Biosciences (ASTM) (+39%), Jazz Pharmaceuticals (JAZZ) (+34%), Repros Therapeutics (RPRX) (+23%), and Curis (CRIS) (+19%).



It was Hep C-apalooza in Boston this week at the American Association for the Study of Liver Disease (AASLD) annual meeting, which included important updates from Vertex Pharmaceuticals (VRTX), Merck (MRK) and others.

One guy who didn't enjoy his time at AASLD was Dr. Yves Benhamou, arrested on criminal fraud charges for allegedly tipping off a hedge fund with insider information about negative clinical trial results.

Bad Medicine: When Doctors Tip Off Wall Street.

Cell Therapeutics (CTIC) submitted the lymphoma drug pixantrone for European approval.

The top FDA drug approval pickers.

GenVec (GNVC) received no bidders for the company.

Fear the Beard! The San Francisco Giants win the World Series!

FDA approves Cadence Pharmaceuticals' (CADX) injectable painkiller Ofirmev but investors sell the stock.

FDA review of Bristol-Myers Squibb's (BMY) melanoma drug Ipilimumab extended three months. The new approval decision date is March 25, 2010.

Questcor Pharmaceuticals (QCOR) launches Acthar as a treatment for infantile spasms.

The week's worst-performing stocks: Biodel (BIOD) (-48%), Angiotech Pharmaceuticals (ANPI) (-44%), AspenBio Pharma (APPY) (-29%), ARYx Therapeutics (ARYX) (-20%), and Anthera Pharmaceuticals (ANTH) (-15%).

Adventrx Pharmaceuticals (ANX) submits FDA approval application for the chemotherapy drug exelbine (ANX-530).

Biogen Idec (BIIB) fires 15% of its workforce as part of a corporate restructuring and cost-cutting plan.

FDA Drug Approvals for October

Dendreon (DNDN): Provenge sales, guidance fall short.

Exact Sciences (EXAS) prices 10 million shares at $6 a share.

MannKind (MNKD) Accused of Data Fraud Coverup.

This week's Biotech Stock Mailbag: Orexigen Therapeutics (OREX), Exact Sciences, Spectrum Pharmaceuticals (SPPI), Avanir Pharmaceuticals and MannKind.

Savient (SVNT) Pharmaceuticals to launch gout drug Krystexxa on Nov. 30.

Roche offers secret rebates to doctors who prescribe eye drug (via New York Times)

CT scans help detect early lung cancer in smokers (via New York Times)

Biovail (now Valeant Pharmaceuticals (VRX) to hedge fund: I'm sorry! (via Pharmalot)

Roche melanoma drug show promise (via Reuters)

Conflict of interest rules: Going too far? Judging by the low quality of recent FDA advisory panels, the answer is definitely "yes!" (via Pharmalot)

--Written by Adam Feuerstein in Boston.



>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Stock quotes in this article: VRTX, AVNR, MNKD, CADX, BIIB, DNDN, BIOD 
Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,501.65 -12.72 -0.08%
S&P 500 1,875.39 -4.16 -0.22%
NASDAQ 4,126.9670 -34.4910 -0.83%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs